Anuh Pharma Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹185 Cr −0.5% YoYSee revenue, profit and what management said. You are viewing Q4 FY26.
AP

Anuh Pharma Ltd

Q4 FY26Pharmaceuticals & Biotechnology

Anuh Pharma Q4 FY26 earnings call: Revenue & Margins

Q4 FY26 investor presentation: what the company reported on revenue, margins and capex.

Revenue
₹202Cr
+2% YoY
+2.5% QoQ
Net profit
₹12Cr
0% YoY
−7.7% QoQ
Margin
10%
+1 pp YoY
0 pp QoQ

Based on Anuh Pharma Ltd's Q4 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

Price₹91
Market cap₹937 Cr
P/E21.2

The short version

Q4 FY26 Revenue: Rs. 202.12 Cr., a 2.50% increase quarter-on-quarter (Page 14). Quarterly EBITDA (Q4 FY26): Rs. 18.63 Cr., down 10.91% QoQ (Page 14).

From Anuh Pharma Ltd's Q4 FY26 earnings-call transcript · updated 24 Sept 2026.

Revenue & Sales Performance

  • Q4 FY26 Revenue: Rs. 202.12 Cr., a 2.50% increase quarter-on-quarter (Page 14)
  • FY26 Revenue: Rs. 776 Cr., a 15.66% increase year-on-year (Pages 7 and 14)
  • Q4 FY26 Total Production: 426 MT, slight change (-0.04%) quarter-on-quarter (Page 6)
  • FY26 Total Production: 1733 MT, a 24.99% increase year-on-year (Page 6)

2 more points from Anuh Pharma Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Anuh Pharma Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

It mentions the following related points: - Continued investments in compliance, operational efficiency, and capacity enhancement are underway to support long-term sustainable growth (Page 35). - Extensive volume expansions across API lines are contributing to growth (Page 35). - A dedicated 10,000 sq. ft. in-house R&D facility with 16 scientists supports product and process innovation for future market penetration (Page 33).

2 more points from Anuh Pharma Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Anuh Pharma Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

See what Anuh Pharma Ltd said on order book & pipeline — free account, 30 seconds.

Anuh Pharma Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Anuh Pharma Ltd Q4 FY26 results — key figures

Anuh Pharma Ltd Q4 FY26 reported results vs Q4 FY25, ₹ crore
₹ CrQ4 FY26Q4 FY25YoYQ3 FY26QoQ
Revenue202198+2%197+2.5%
Operating profit (EBITDA)2019+5.3%19+5.3%
Operating margin10%9%+1 pp10%0 pp
Profit before tax1617-5.9%18-11.1%
Net profit (PAT)12120%13-7.7%
EPS (₹)1.171.24-5.6%1.34-12.7%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹185 Cr, net profit ₹11 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • Balaxi Pharma (Q4 FY26)

    Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22). Key investor presentation takeaways from Balaxi Pharma's Q4 FY

  • Accretion Pharmaceuticals (Q4 FY26)

    45.89 crore, up 18.24% YoY (Page 28). Key investor presentation takeaways from Accretion Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how it ranks

  • Gujarat Themis Biosyn (Q4 FY26)

    . Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation — and how it ranks against sector peers.

  • Aptus Pharma (Q4 FY26)

    The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Anuh Pharma Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Anuh Pharma Ltd Q4 FY26 results?

Q4 FY26 Revenue: Rs. 202.12 Cr., a 2.50% increase quarter-on-quarter (Page 14). Quarterly EBITDA (Q4 FY26): Rs. 18.63 Cr., down 10.91% QoQ (Page 14).

What is Anuh Pharma Ltd share price analysis?

Anuh Pharma Ltd currently shows a neutral. The stock trades at a P/E of 21.2 with a market cap of ₹937 Cr. Investors should review the full earnings analysis for detailed insights.

Keep Anuh Pharma Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.